The study is testing a new treatment for triple negative breast cancer. The new treatment includes four drugs called atezolizumab, bevacizumab, gemcitabine, and carboplatin.
Patients who have been recently diagnosed with triple negative breast cancer that is locally advanced and cannot be removed by surgery, or has already spread to other parts of the body (known as metastatic triple-negative breast cancer).
2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.
When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.
Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.